Estimated effectiveness of vaccines and extended half-life monoclonal antibodies against respiratory syncytial virus (RSV) hospitalizations in young children
Zheng, Z.; Weinberger, D. M.; Pitzer, V. E.
Show abstract
Several vaccines and extended half-life monoclonal antibodies (mAbs) against RSV infection have shown promising progress in clinical trials. Aiming to project the impact of various prevention strategies against RSV hospitalizations in young children, we applied age-structured transmission models to evaluate prevention strategies including maternal immunization, live-attenuated vaccines, and long-lasting mAbs. Our results suggest that maternal immunization and long-lasting mAbs are highly effective in preventing RSV hospitalizations in infants under 6 months of age, averting more than half of RSV hospitalizations in neonates. Live-attenuated vaccines could reduce RSV hospitalizations in vaccinated age groups and are also predicted to have a modest effect in unvaccinated age groups because of disruptions to transmission. A seasonal vaccination program at the country level at most provides a minor advantage regarding efficiency. Our findings highlight the substantial public health impact that upcoming RSV prevention strategies may provide.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants 96%
- Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales 96%
- Projecting the impact of a two-dose COVID-19 vaccination campaign in Ontario, Canada 95%
Similar papers in this journal
- Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: a modelling study 95%
- Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria 94%
- Benefit-Risk Assessment Of COVID-19 Vaccine, Mrna (Mrna-1273) For Males Age 18-64 Years 93%
Similar papers in this journal
- Potential health and economic impact of paediatric vaccination using next generation influenza vaccines in Kenya: a modelling study 95%
- Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis 95%
- Transient increased risk of influenza infection following RSV infection in South Africa; findings from the PHIRST study, South Africa, 2016-2018 94%
Similar papers in this journal
Similar papers in this journal
- Cost-Effectiveness of Prefusion F Protein-Based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States 97%
- The impact of vaccination on COVID-19 outbreaks in the United States 95%
- Effectiveness of Influenza Vaccines in the HIVE household cohort over 8 years: is there evidence of indirect protection? 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.